In people suffering from severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) and related comorbidities, intervention with dupilumab is efficacious and well-tolerated.

A multicentric, observational, prospective study in real-life aimed to assess safety and effectiveness of dupilumab in adults having severe asthma and CRSwNP graded by common overlapping comorbid situations.

In this study, adults (n = 82) with severe CRSwNP who had initiated dupilumab intervention in the context of standard care were recruited. Collection of data was done and several efficacy parameters were utilized. Utilizing the Wilcoxon test for paired data, a comparison of the patient data was done. Using SPSS version 20, all the statistical evaluations were done.

A profound betterment was identified for all applied effectiveness parameters like: (i)  Dermatology Life Quality Index (DLQI) and Eczema Area and Severity Index (EASI) scores for atopic dermatitis, (ii) Asthma Quality of Life Questionnaire (AQLQ) and Forced Expiratory Volume in the 1st second (FEV1) scores for asthma, (iii) Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) and Rhinitis Control Scoring System (RCSS) scores for allergic perennial rhinitis, and (iv) bilateral endoscopic nasal polyp score (NPS) and 22-item Sino-Nasal Outcome Test (SNOT-22) scores for CRSwNP.

For chronic spontaneous urticaria, an insignificant enhancement was attained in Urticaria Activity Score over 7 days (UAS7). Intervention with dupilumab illustrated good tolerability.

The IgG4 monoclonal antibody dupilumab is effective for the management of people diagnosed with CRSwNP and related comorbidities.